Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Epigral Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Kaushal Soparkar

İcra Kurulu Başkanı

₹43.9m

Toplam tazminat

CEO maaş yüzdesi	9.2%
CEO görev süresi	8.4yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	8.4yrs

Son yönetim güncellemeleri

Recent updates

Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Jul 04

Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price

Nov 22

CEO Tazminat Analizi

Kaushal Soparkar'un ücretlendirmesi Epigral'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹44m	₹4m	₹2b
Dec 31 2023	n/a	n/a	₹2b
Sep 30 2023	n/a	n/a	₹2b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹62m	₹4m	₹4b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹4b
Jun 30 2022	n/a	n/a	₹3b
Mar 31 2022	₹32m	₹4m	₹3b
Mar 31 2021	₹30m	₹3m	₹1b
Mar 31 2020	₹28m	₹4m	₹1b
Mar 31 2019	₹64m	₹4m	₹2b
Mar 31 2018	₹9m	₹4m	₹2b

Tazminat ve Piyasa: Kaushal 'nin toplam tazminatı ($USD 522.84K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 365.32K ).

Tazminat ve Kazançlar: Kaushal 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Kaushal Soparkar (41 yo)

8.4yrs

Görev süresi

₹43,907,000

Tazminat

Mr. Kaushal Ashisbhai Soparkar serves as Chief Executive Officer and until August 5, 2023 served as Managing Director and serves as Director of Epigral Limited (formerly known as Meghmani Finechem Limited)...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Maulik Patel	Chairman & MD	8.4yrs	₹43.91m	7.81% ₹ 7.4b
Kaushal Soparkar	CEO & Executive Director	8.4yrs	₹43.91m	0.53% ₹ 508.2m
Kanubhai Patel	Independent Non-Executive Director	3.4yrs	₹700.00k	Veri yok
Karana Patel	Non-Executive Director	8.4yrs	₹25.32m	1.74% ₹ 1.7b
Sanjay Asher	Independent Non-Executive Director	3.4yrs	₹500.00k	Veri yok
Ankit Patel	Non-Executive Director	8.4yrs	₹41.27m	5.62% ₹ 5.3b
Manubhai Patel	Independent Non-Executive Director	7.4yrs	₹875.00k	Veri yok
Darshan Patel	Non-Executive Director	8.4yrs	₹17.35m	2.37% ₹ 2.3b
Nirali Parikh	Independent Non-Executive (Woman) Director	9.6yrs	₹725.00k	Veri yok
Raju Swamy	Independent Non-Executive Director	3.4yrs	₹400.00k	0.010% ₹ 9.9m

8.4yrs

Ortalama Görev Süresi

43yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EPIGRAL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.4 yıldır).

Epigral Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Epigral Limited, Annual General Meeting, Jul 09, 2024

Insufficient new directors

Insider recently bought ₹4.8m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Insider recently bought ₹4.6m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Recent updates

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: ₹20.67 (vs ₹7.58 in 1Q 2024)

Investor sentiment improves as stock rises 15%

Epigral Limited to Report Q1, 2025 Results on Jul 24, 2024

Epigral Limited Approves Final Dividend for the Financial Year 2024

Epigral Limited Approves Final Dividend for the Financial Year 2024

Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings released: EPS: ₹47.14 (vs ₹85.03 in FY 2023)

Epigral Limited, Annual General Meeting, Jul 09, 2024

Insufficient new directors

Full year 2024 earnings released: EPS: ₹47.13 (vs ₹85.03 in FY 2023)

Epigral Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump

Epigral Limited to Report Q4, 2024 Results on Apr 22, 2024

Investor sentiment improves as stock rises 22%

Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward

Investor sentiment improves as stock rises 23%

Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2024 earnings released: EPS: ₹11.81 (vs ₹18.58 in 3Q 2023)

Now 23% overvalued after recent price rise

Epigral Limited to Report Q3, 2024 Results on Jan 24, 2024

Second quarter 2024 earnings released: EPS: ₹9.14 (vs ₹22.04 in 2Q 2023)

Epigral Limited to Report Q2, 2024 Results on Nov 06, 2023

First quarter 2024 earnings released: EPS: ₹7.58 (vs ₹25.94 in 1Q 2023)

Meghmani Finechem Limited to Report Q1, 2024 Results on Aug 05, 2023

Meghmani Finechem Limited Approves Final Equity Dividend for the Financial Year 2022-2023

Upcoming dividend of ₹2.50 per share at 0.5% yield

Insider recently bought ₹4.8m worth of stock

Meghmani Finechem Limited Proposes Final Dividend to the Shareholders for Financial Year 2022- 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Insider recently bought ₹4.6m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong

Investor sentiment improves as stock rises 15%

Chairman & MD recently bought ₹4.8m worth of stock

Chairman & MD recently bought ₹2.9m worth of stock

Insider recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹18.68 (vs ₹23.85 in 3Q 2022)

Meghmani Finechem Limited Declares Maiden Interim Dividend for the Year Financial Year 2022-23, Payable on or After 08 February, 2023

Meghmani Finechem Limited to Report Q3, 2023 Results on Jan 19, 2023

Second quarter 2023 earnings released: EPS: ₹22.04 (vs ₹23.85 in 2Q 2022)

With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released: EPS: ₹25.94 (vs ₹7.89 in 1Q 2022)

Meghmani Finechem Limited to Report Q1, 2023 Results on Jul 21, 2022

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022

Investor sentiment improved over the past week

Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Investor sentiment improved over the past week

Meghmani Finechem Limited to Report Fiscal Year 2022 Results on Apr 25, 2022

Investor sentiment improved over the past week

CEO, MD & Director recently bought ₹799k worth of stock

Insider recently bought ₹762k worth of stock

Investor sentiment improved over the past week

Insider recently bought ₹8.3m worth of stock

Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price

Investor sentiment improved over the past week

No independent directors

No independent directors

No independent directors

CEO, MD & Director recently bought ₹5.0m worth of stock